Who
Douglas B. Snyder
SVP, General Counsel
Company insider
Files Form 4 as: SVP, General Counsel, IDEAYA Biosciences; Chief Legal Officer, Gw Pharmaceuticals.
In numbers
- Trades disclosed
- 70
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $1.2M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 26 Feb 2019
- Last trade
- 30 Jan 2026
- Last filed
- 2 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jan 2026filed 2 Feb 2026 | IDYA IDEAYA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | IDYA IDEAYA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 28 Nov 2025filed 2 Feb 2026 | IDYA IDEAYA BiosciencesBiotechnology | SEC FORM 4 Code A | $18K1,041 at $16.91 | filing |
| 28 Nov 2025filed 2 Feb 2026 | IDYA IDEAYA BiosciencesBiotechnology | SEC FORM 4 Code A | $18K1,041 at $16.91 | filing |
| 30 May 2025filed 2 Feb 2026 | IDYA IDEAYA BiosciencesBiotechnology | SEC FORM 4 Code A | $18K1,039 at $16.91 | filing |
| 30 May 2025filed 2 Feb 2026 | IDYA IDEAYA BiosciencesBiotechnology | SEC FORM 4 Code A | $18K1,039 at $16.91 | filing |
| 27 Feb 2025filed 28 Feb 2025 | IDYA IDEAYA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,000 at $0.00 | filing |
| 26 Sep 2024filed 27 Sep 2024 | IDYA IDEAYA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticals | SEC FORM 4 Code D | —61,848 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —82,956 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —63,252 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —46,644 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —9,180 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —9,612 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —88,524 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —13,272 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —149,856 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —89,952 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —45,360 | filing |
| 5 May 2021filed 7 May 2021 | Gw Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —72,528 | filing |
News
No headline names them, or the companies they trade most, lately.